Tarun Tyagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tarun Tyagi has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Neha Gupta
Jamia Millia Islamia, India
6 shared publications Anita Sahu
Defense Institute of Physiology and Allied Sciences, Defense Research and Development Organisation, Delhi, India
5 shared publicationsVelu Nair
Armed Forces Medical College, Pune, Maharashtra, India
5 shared publicationsAmit Prabhakar
Defense Institute of Physiology and Allied Sciences, Defense Research and Development Organisation, Delhi, India
4 shared publicationsBabita Kumari
Defense Institute of Physiology and Allied Sciences, Defense Research and Development Organisation, Delhi, India
4 shared publicationsTathagata Chatterjee
Army Hospital (Research and Referral), New Delhi, India
4 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4)
Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding
- 19 May 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4)
Open AccessReal-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding
- Open Access
- 28 October 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Current understanding of tumor immunosuppressive mechanisms forms the basis for modern day immunotherapies. Immunoregulatory role of platelets in cancer remains largely elusive. Platelets from non-small cell lung cancer (NSCLC) patients revealed a distinct activation phenotype. TREM-like transcript 1 (TLT-1), a platelet protein, was increased along with enhanced extracellular release from NSCLC platelets. The increased platelet TLT-1 was also evident in humanized mice with patient-derived tumors. In immunocompetent mice with syngeneic tumors, TLT-1 binding to T cells, in vivo, led to suppression of CD8 T cells, promoting tumor growth. We identified direct interaction between TLT-1 and CD3ε on T cells, implicating the NF-κB pathway in CD8 T cell suppression. Anti–TLT-1 antibody rescued patients’ T cells from platelet-induced suppression ex vivo and reduced tumors in mice in vivo. Clinically, higher TLT-1 correlated with reduced survival of NSCLC patients. Our findings thus identify TLT-1 as a platelet-derived immunosuppressor that suppresses CD8 T cells and demonstrate its therapeutic and prognostic significance in cancer.
- 28 October 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Open AccessPlatelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Current understanding of tumor immunosuppressive mechanisms forms the basis for modern day immunotherapies. Immunoregulatory role of platelets in cancer remains largely elusive. Platelets from non-small cell lung cancer (NSCLC) patients revealed a distinct activation phenotype. TREM-like transcript 1 (TLT-1), a platelet protein, was increased along with enhanced extracellular release from NSCLC platelets. The increased platelet TLT-1 was also evident in humanized mice with patient-derived tumors. In immunocompetent mice with syngeneic tumors, TLT-1 binding to T cells, in vivo, led to suppression of CD8 T cells, promoting tumor growth. We identified direct interaction between TLT-1 and CD3ε on T cells, implicating the NF-κB pathway in CD8 T cell suppression. Anti–TLT-1 antibody rescued patients’ T cells from platelet-induced suppression ex vivo and reduced tumors in mice in vivo. Clinically, higher TLT-1 correlated with reduced survival of NSCLC patients. Our findings thus identify TLT-1 as a platelet-derived immunosuppressor that suppresses CD8 T cells and demonstrate its therapeutic and prognostic significance in cancer.
- Open Access
- 1 September 2019
- Published by Elsevier in EBioMedicine
- Vol. 47, 31-32
Author's response to “platelet antioxidants: A conundrum in aging”
- 1 September 2019
- Published by Elsevier in EBioMedicine
- Vol. 47, 31-32
Open AccessAuthor's response to “platelet antioxidants: A conundrum in aging”
- 29 July 2019
- Published by Springer Nature in Nature Genetics
- Vol. 51 (8) , 1233-1243
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Factors that underlie the clustering of metabolic syndrome traits are not fully known. We performed whole-exome sequence analysis in kindreds with extreme phenotypes of early-onset atherosclerosis and metabolic syndrome, and identified novel loss-of-function mutations in the gene encoding the pancreatic elastase chymotrypsin-like elastase family member 2A (CELA2A). We further show that CELA2A is a circulating enzyme that reduces platelet hyperactivation, triggers both insulin secretion and degradation, and increases insulin sensitivity. CELA2A plasma levels rise postprandially and parallel insulin levels in humans. Loss of these functions by the mutant proteins provides insight into disease mechanisms and suggests that CELA2A could be an attractive therapeutic target.
- 29 July 2019
- Published by Springer Nature in Nature Genetics
- Vol. 51 (8) , 1233-1243
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Factors that underlie the clustering of metabolic syndrome traits are not fully known. We performed whole-exome sequence analysis in kindreds with extreme phenotypes of early-onset atherosclerosis and metabolic syndrome, and identified novel loss-of-function mutations in the gene encoding the pancreatic elastase chymotrypsin-like elastase family member 2A (CELA2A). We further show that CELA2A is a circulating enzyme that reduces platelet hyperactivation, triggers both insulin secretion and degradation, and increases insulin sensitivity. CELA2A plasma levels rise postprandially and parallel insulin levels in humans. Loss of these functions by the mutant proteins provides insight into disease mechanisms and suggests that CELA2A could be an attractive therapeutic target.
- Open Access
- 1 June 2019
- Published by Elsevier in EBioMedicine
- Vol. 44, 28-40
Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
- 1 June 2019
- Published by Elsevier in EBioMedicine
- Vol. 44, 28-40
Open AccessAge associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
- 12 March 2019
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 119 (05) , 744-757
Epithelial (E)-Cadherin is a Novel Mediator of Platelet Aggregation and Clot Stability
Cadherins play a major role in mediating cell–cell adhesion, which shares many parallels with platelet–platelet interactions during aggregate formation and clot stabilization. Platelets express epithelial (E)-cadherin, but its contribution to platelet function and/or platelet production is currently unknown. To assess the role of E-cadherin in platelet production and function in vitro and in vivo, we utilized a megakaryocyte-specific E-cadherin knockout mouse model. Loss of E-cadherin in megakaryocytes does not affect megakaryocyte maturation, platelet number or size. However, platelet dysfunction in the absence of E-cadherin is revealed when conditional knockout mice are challenged with acute antibody-mediated platelet depletion. Unlike wild-type mice that recover fully, knockout mice die within 72 hours post-antibody administration, likely from haemorrhage. Furthermore, conditional knockout mice have prolonged tail bleeding times, unstable clot formation, reduced clot retraction and reduced fibrin deposition in in vivo injury models. Murine platelet aggregation in vitro in response to thrombin and thrombin receptor activating peptide is compromised in E-cadherin null platelets, while aggregation in response to adenosine diphosphate (ADP) is not significantly different. Consistent with this, in vitro aggregation of primary human platelets in response to thrombin is decreased by an inhibitory E-cadherin antibody. Integrin activation and granule secretion in response to ADP and thrombin are not affected in E-cadherin null platelets, but Akt and glycogen synthase kinase 3β (GSK3β) activation are attenuated, suggesting a that E-cadherin contributes to aggregation, clot stabilization and retraction that is mediated by phosphoinositide 3-kinase/Akt/GSK3β signalling. In summary, E-cadherin plays a salient role in platelet aggregation and clot stability. * These authors contributed equally to this work.
- 12 March 2019
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 119 (05) , 744-757
Epithelial (E)-Cadherin is a Novel Mediator of Platelet Aggregation and Clot Stability
Cadherins play a major role in mediating cell–cell adhesion, which shares many parallels with platelet–platelet interactions during aggregate formation and clot stabilization. Platelets express epithelial (E)-cadherin, but its contribution to platelet function and/or platelet production is currently unknown. To assess the role of E-cadherin in platelet production and function in vitro and in vivo, we utilized a megakaryocyte-specific E-cadherin knockout mouse model. Loss of E-cadherin in megakaryocytes does not affect megakaryocyte maturation, platelet number or size. However, platelet dysfunction in the absence of E-cadherin is revealed when conditional knockout mice are challenged with acute antibody-mediated platelet depletion. Unlike wild-type mice that recover fully, knockout mice die within 72 hours post-antibody administration, likely from haemorrhage. Furthermore, conditional knockout mice have prolonged tail bleeding times, unstable clot formation, reduced clot retraction and reduced fibrin deposition in in vivo injury models. Murine platelet aggregation in vitro in response to thrombin and thrombin receptor activating peptide is compromised in E-cadherin null platelets, while aggregation in response to adenosine diphosphate (ADP) is not significantly different. Consistent with this, in vitro aggregation of primary human platelets in response to thrombin is decreased by an inhibitory E-cadherin antibody. Integrin activation and granule secretion in response to ADP and thrombin are not affected in E-cadherin null platelets, but Akt and glycogen synthase kinase 3β (GSK3β) activation are attenuated, suggesting a that E-cadherin contributes to aggregation, clot stabilization and retraction that is mediated by phosphoinositide 3-kinase/Akt/GSK3β signalling. In summary, E-cadherin plays a salient role in platelet aggregation and clot stability. * These authors contributed equally to this work.
- 4 June 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (07) , 1279-1295
Genome-Wide Expression Analysis Suggests Hypoxia-Triggered Hyper-Coagulation Leading to Venous Thrombosis at High Altitude
Venous thromboembolism (VTE), a multi-factorial disease, is the third most common cardiovascular disease. Established genetic and acquired risk factors are responsible for the onset of VTE. High altitude (HA) also poses as an additional risk factor, predisposing individuals to VTE; however, its molecular mechanism remains elusive. This study aimed to identify genes/pathways associated with the pathophysiology of deep vein thrombosis (DVT) at HA. Gene expression profiling of DVT patients, who developed the disease, either at sea level or at HA-DVT locations, resulted in differential expression of 378 and 875 genes, respectively. Gene expression profiles were subjected to bioinformatic analysis, followed by technical and biological validation of selected genes using quantitative reverse transcription-polymerase chain reaction. Both gene ontology and pathway analysis showed enrichment of genes involved in haemostasis and platelet activation in HA-DVT patients with the most relevant pathway being ‘response to hypoxia’. Thus, given the environmental condition the differential expression of hypoxia-responsive genes (angiogenin, ribonuclease, RNase A family, 5; early growth response 1; lamin A; matrix metallopeptidase 14 [membrane-inserted]; neurofibromin 1; PDZ and LIM domain 1; procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1; solute carrier family 6 [neurotransmitter transporter, serotonin], member 4; solute carrier family 9 [sodium/hydrogen exchanger], member 1; and TEK tyrosine kinase, endothelial) in HA-DVT could be a determining factor to understand the pathophysiology of DVT at HA. P.K.J. and A.S. performed the experiments, analysed the data and wrote the manuscript; A.P. and B.K. performed the real-time PCR experiments; P.A., J.N. and J.S. performed the microarray experiments; T.C., N.B. and V.N. participated in the clinical part of the study; T.T., M.S. and N.G. edited the manuscript; M.Z.A. designed the study, interpreted the data and drafted the manuscript. P.K.J. and A.S. contributed equally to this study. * These authors contributed equally to the manuscript. # Present address: Department of Biotechnology, Jamia Millia Islamia, New Delhi-110025, India (e-mail: [email protected]).
- 4 June 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (07) , 1279-1295
Genome-Wide Expression Analysis Suggests Hypoxia-Triggered Hyper-Coagulation Leading to Venous Thrombosis at High Altitude
Venous thromboembolism (VTE), a multi-factorial disease, is the third most common cardiovascular disease. Established genetic and acquired risk factors are responsible for the onset of VTE. High altitude (HA) also poses as an additional risk factor, predisposing individuals to VTE; however, its molecular mechanism remains elusive. This study aimed to identify genes/pathways associated with the pathophysiology of deep vein thrombosis (DVT) at HA. Gene expression profiling of DVT patients, who developed the disease, either at sea level or at HA-DVT locations, resulted in differential expression of 378 and 875 genes, respectively. Gene expression profiles were subjected to bioinformatic analysis, followed by technical and biological validation of selected genes using quantitative reverse transcription-polymerase chain reaction. Both gene ontology and pathway analysis showed enrichment of genes involved in haemostasis and platelet activation in HA-DVT patients with the most relevant pathway being ‘response to hypoxia’. Thus, given the environmental condition the differential expression of hypoxia-responsive genes (angiogenin, ribonuclease, RNase A family, 5; early growth response 1; lamin A; matrix metallopeptidase 14 [membrane-inserted]; neurofibromin 1; PDZ and LIM domain 1; procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1; solute carrier family 6 [neurotransmitter transporter, serotonin], member 4; solute carrier family 9 [sodium/hydrogen exchanger], member 1; and TEK tyrosine kinase, endothelial) in HA-DVT could be a determining factor to understand the pathophysiology of DVT at HA. P.K.J. and A.S. performed the experiments, analysed the data and wrote the manuscript; A.P. and B.K. performed the real-time PCR experiments; P.A., J.N. and J.S. performed the microarray experiments; T.C., N.B. and V.N. participated in the clinical part of the study; T.T., M.S. and N.G. edited the manuscript; M.Z.A. designed the study, interpreted the data and drafted the manuscript. P.K.J. and A.S. contributed equally to this study. * These authors contributed equally to the manuscript. # Present address: Department of Biotechnology, Jamia Millia Islamia, New Delhi-110025, India (e-mail: [email protected]).
- Open Access
- 1 December 2017
- Published by Elsevier in EBioMedicine
- Vol. 26, 175-186
MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis
- 1 December 2017
- Published by Elsevier in EBioMedicine
- Vol. 26, 175-186
Open AccessMicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis
- 18 April 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (18) , 4763-4768
Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia
Significance: Hypoxia predisposes otherwise healthy individuals to venous thrombosis, but the underlying mechanism has been unclear. Our study revealed a causal role for nucleotide binding domain, leucine-rich-containing family, pyrin domain containing 3 (NLRP3) inflammasome and IL-1β during hypoxia-induced venous thrombosis. We further show a direct association between NLRP3 and hypoxia-inducible factor 1-alpha (HIF-1α) during these conditions. Specific interventions within the hypoxia–HIF-1α–NLRP3–IL-1β axis in the venous milieu significantly reduced venous thrombosis in our animal model. Notably, we also observed modulation of similar pathways in patients diagnosed with altitude-induced venous thrombosis. Our study thus revealed thrombosis at high altitude to be centrally regulated by a complex network of coagulatory and inflammatory processes, critically linked through HIF-1α.
- 18 April 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (18) , 4763-4768
Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia
Significance: Hypoxia predisposes otherwise healthy individuals to venous thrombosis, but the underlying mechanism has been unclear. Our study revealed a causal role for nucleotide binding domain, leucine-rich-containing family, pyrin domain containing 3 (NLRP3) inflammasome and IL-1β during hypoxia-induced venous thrombosis. We further show a direct association between NLRP3 and hypoxia-inducible factor 1-alpha (HIF-1α) during these conditions. Specific interventions within the hypoxia–HIF-1α–NLRP3–IL-1β axis in the venous milieu significantly reduced venous thrombosis in our animal model. Notably, we also observed modulation of similar pathways in patients diagnosed with altitude-induced venous thrombosis. Our study thus revealed thrombosis at high altitude to be centrally regulated by a complex network of coagulatory and inflammatory processes, critically linked through HIF-1α.
- 1 August 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 23 (5) , 429-437
Endothelin-1 Gene Polymorphism and Its Level Predict the Risk of Venous Thromboembolism in Male Indian Population
Genes related to endothelial function are responsible for the regulation of vascular functions. The aim of this study is to investigate whether endothelial gene-associated polymorphism and their plasma levels can be used to predict the risk for venous thromboembolism (VTE). We studied 133 patients with VTE and 164 healthy controls. Endothelin (EDN) G8002A, EDN T1370G, EDN 3A/4A, eNOSG894T, angiotensin-converting enzyme I/D, vascular endothelial growth factor C936T, and endothelial cell protein C receptor A6936G polymorphism was genotyped by restriction fragment length polymorphism. Plasma levels of endothelin 1 (EDN1), endothelial nitric oxide synthase, and angiotensin-converting enzyme were measured by enzyme-linked immunoassay kit. The genotype and allele frequency between control and patients with VTE were significantly altered only for EDN T1370G polymorphism. The plasma EDN1 concentration was relatively higher in patients with VTE (P = .0017) compared to healthy controls and showed an association with the EDN1 gene polymorphism in male Indian population. Logistic regression model analysis for EDN T1370G indicated a significant association between EDN G allele and occurrence of VTE. The EDN1 gene polymorphism may play a significant role in predicting individual’s susceptibility toward VTE and its clinical progression.
- 1 August 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 23 (5) , 429-437
Endothelin-1 Gene Polymorphism and Its Level Predict the Risk of Venous Thromboembolism in Male Indian Population
Genes related to endothelial function are responsible for the regulation of vascular functions. The aim of this study is to investigate whether endothelial gene-associated polymorphism and their plasma levels can be used to predict the risk for venous thromboembolism (VTE). We studied 133 patients with VTE and 164 healthy controls. Endothelin (EDN) G8002A, EDN T1370G, EDN 3A/4A, eNOSG894T, angiotensin-converting enzyme I/D, vascular endothelial growth factor C936T, and endothelial cell protein C receptor A6936G polymorphism was genotyped by restriction fragment length polymorphism. Plasma levels of endothelin 1 (EDN1), endothelial nitric oxide synthase, and angiotensin-converting enzyme were measured by enzyme-linked immunoassay kit. The genotype and allele frequency between control and patients with VTE were significantly altered only for EDN T1370G polymorphism. The plasma EDN1 concentration was relatively higher in patients with VTE (P = .0017) compared to healthy controls and showed an association with the EDN1 gene polymorphism in male Indian population. Logistic regression model analysis for EDN T1370G indicated a significant association between EDN G allele and occurrence of VTE. The EDN1 gene polymorphism may play a significant role in predicting individual’s susceptibility toward VTE and its clinical progression.